Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 450

Sort by

Sort Order Select

Journal Articles

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma

Blood blood.2025030151.

https://doi.org/10.1182/blood.2025030151

Published: 2025

Includes: Supplemental data

Journal Articles

Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP study

Andrew L. Feldman, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Naoki Oishi, Guangzhen Hu, Pedro Farinha, Catalina Amador, Elías Campo, Wing C. Chan, James R. Cook, Jan Delabie, Kai Fu, Timothy C Greiner, Laura K Hilton, Giorgio GA Inghirami, Javeed Iqbal, Elaine S Jaffe, Ryan Morin, Sarah L. Ondrejka, German Ott, Stefania Pittaluga, Philipp W Raess, Andreas Rosenwald, Kerry J. Savage, Graham W. Slack, Susan L. Slager, Joo Y Song, George Wright, Hao-Wei Wang, Yu Zeng, Tadashi Yoshino, Xiaojun Wu, Ryan A Wilcox, xueju wang, Min Shi, Akira Satou, Anamarija M Perry, Roberto Nicolas Miranda, L.Jeffrey Jeffrey Medeiros, Matthew J Maurer, Eric Mou, Young Hyeh Ko, Kennosuke Karube, Brad S Kahl, Liuyan Jiang, David L Jaye, Alejandro Gru, Laurence L de Leval, Weina Chen, Jennifer R. Chapman, James R Cerhan, Carlos Barrionuevo, Stephen M. Ansell, Ahmed Aljudi

Blood blood.2024027700.

https://doi.org/10.1182/blood.2024027700

Published: 2025

Includes: Supplemental data

Journal Articles

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

Max S. Topp, Matthew Matasar, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O’Brien, Uri Abadi, Irit Avivi, Yuan Cheng, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie

Blood (2025) 145 (14): 1498–1509.

https://doi.org/10.1182/blood.2024027044

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Christopher J. Forlenza, Opeyemi Jegede, Stephen M. Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E. Amengual, Peter D. Cole, Brad S. Kahl, Catherine S. Diefenbach

Blood (2024) 144 (Supplement 1): 4427.

https://doi.org/10.1182/blood-2024-201624

Published: 2024

Journal Articles

BCL2 Expression Correlates with New Molecular Classification of Anaplastic Large Cell Lymphoma

Jimena B. Gimenez, Min Shi, Naoki Oishi, Liuyan Jiang, Farah M. Salama, Jennifer R. Chapman-Fredricks, Weina Chen, Jagmohan Sidhu, Xiaojun Wu, Stephen M. Ansell, Guangzhen Hu, Andrew L. Feldman

Blood (2024) 144 (Supplement 1): 4381.

https://doi.org/10.1182/blood-2024-208516

Published: 2024

Journal Articles

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Bruce D. Cheson, Nancy L. Bartlett, Betsy R. LaPlant, Hun Ju Lee, Ranjana H. Advani, Beth Christian, Catherine S. Diefenbach, Tatyana Feldman, Stephen M. Ansell

Blood (2024) 144 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2024-207424

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Blood (2024) 144 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2024-201269

Published: 2024

Journal Articles

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2372.

https://doi.org/10.1182/blood-2024-210474

Published: 2024

Journal Articles

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 7589.

https://doi.org/10.1182/blood-2024-210586

Published: 2024

Journal Articles

Polymorphonuclear Myeloid-Derived Suppressor Cells Promote Tumor Cell Survival and Suppress Cytotoxic T- Cells in Waldenström Macroglobulinemia

Vaishali Bhardwaj, Zhi-Zhang Yang, Prithviraj Mukherjee, Rekha Mudappathi, Junewen Wang, Xinyi Tang, Jonas Paludo, Anne J. Novak, Patrizia Mondello, Stephen M. Ansell

Blood (2024) 144 (Supplement 1): 5661.

https://doi.org/10.1182/blood-2024-208966

Published: 2024

Journal Articles

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Blood (2024) 144 (Supplement 1): 6201.

https://doi.org/10.1182/blood-2024-205509

Published: 2024

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 570.

https://doi.org/10.1182/blood-2024-199845

Published: 2024

Journal Articles

Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Adi Zoref-Lorenz, Elliot J Cahn, Eric Mou, Yucai Wang, Matthew J. Maurer, Andrew L. Feldman, Bri J Negaard, Raphael Mwangi, Gilad Itchaki, Grzegorz S. Nowakowski, Thomas M. Habermann, Brian K. Link, Stephen M. Ansell, Anne J. Novak, Gaurav Goyal, Thomas E. Witzig, James R. Cerhan, Michael B. Jordan

Blood (2024) 144 (Supplement 1): 1624.

https://doi.org/10.1182/blood-2024-210119

Published: 2024

Journal Articles

Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy

Radhika Bansal, Andre Corraes, Monica Shaw, Lucy Holmes, Allison Kosobud, Kelsey L Haugen, Arushi Khurana, Paul J. Hampel, Urshila Durani, Suzanne R Hayman, Yucai Wang, Moritz Binder, Jonas Paludo, Saad S. Kenderian, N. Nora Bennani, Patrick B. Johnston, Stephen M. Ansell, Yi Lin

Blood (2024) 144 (Supplement 1): 2274.

https://doi.org/10.1182/blood-2024-203370

Published: 2024

Journal Articles

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2024-211111

Published: 2024

Journal Articles

Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2024-200408

Published: 2024

Journal Articles

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Matthew Matasar, Max S. Topp, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jingxian Cai, Julia Zecchini, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie

Blood (2024) 144 (Supplement 1): 866.

https://doi.org/10.1182/blood-2024-199155

Published: 2024

Journal Articles

Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience

Jamie Johnston, Katie J. Doane, Wesley Waszak, Carolyn Flock, Arushi Khurana, Nina Logan, Nanci Hawley, Eyad Al-Hattab, Akeem R. Lewis, Jonathan Ticku, Amir Yosef, Stephen M. Ansell, Shaji Kumar, Sameer A. Parikh, Mithun V Shah, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2024) 144 (Supplement 1): 784.

https://doi.org/10.1182/blood-2024-205791

Published: 2024

Journal Articles

Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts

Blood (2024) 144 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2024-194681

Published: 2024

Journal Articles

Characteristics and Outcomes of Incidentally Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)

Suheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, Robyn L Kuchler, Thomas M. Habermann, Matthew J. Maurer, James R. Cerhan, Carrie A Thompson, Yucai Wang, Grzegorz S. Nowakowski, Stephen M. Ansell, Thomas E. Witzig

Blood (2024) 144 (Supplement 1): 1710.

https://doi.org/10.1182/blood-2024-202557

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma

Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP study

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

BCL2 Expression Correlates with New Molecular Classification of Anaplastic Large Cell Lymphoma

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Polymorphonuclear Myeloid-Derived Suppressor Cells Promote Tumor Cell Survival and Suppress Cytotoxic T- Cells in Waldenström Macroglobulinemia

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience

Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts

Characteristics and Outcomes of Incidentally Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only